What type of study is this?

This is a Quantitative Study study.

September 27, 2025Frontiers in ImmunologyOpen Access

Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE

View Full Paper

Ask AI

Bookmark

Authors

LDL.S. DrevetonCharité - Universitätsmedizin Berlin JSJakob Joachim SpenckerHumboldt-Universität zu Berlin HRHéctor Rincón-ArévaloCharité - Universitätsmedizin Berlin

Discussion

Member takes

Implication

Analysis reveals that soluble checkpoint molecules correlate with disease activity and long-term outcomes in SLE patients, suggesting personalized treatment approaches.

Key Points

Higher concentrations of sCD25, sTim-3, and sGal-9 indicate active systemic lupus erythematosus disease.
SLE patients with renal involvement showed significantly elevated levels of soluble immune checkpoint molecules.
Cluster analysis revealed a subset of SLE patients with severe disease had the highest concentrations of these biomarkers.
Low levels of sCD25 were associated with sustained remission in patients utilizing DORIS and LLDAS criteria.

Cite This Study

Dreveton et al. (2025) studied this question.

synapsesocial.com/papers/68d7be66eebfec0fc5237d1e https://doi.org/10.3389/fimmu.2025.1685275

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals that soluble checkpoint molecules correlate with disease activity and long-term outcomes in SLE patients, suggesting personalized treatment approaches.

Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE

Discussion

Member takes

Implication

Key Points

Cite This Study

Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider